Share this article
Share this article
FORT COLLINS, Colo., April 20, 2021 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company creating next generation immune therapies built around proprietary discovery and development technologies, today announced that Stephen Wilson, Ph.D., has joined the company as its Head of Global Innovations, effective April 19, 2021. Dr. Wilson arrives at Cytocom after spending nearly 25 years at the La Jolla Institute for Immunology (LJII) where he was active in biomedical research and served as the research facility's chief operating officer.
As Head of Global Innovation for Cytocom, Dr. Wilson will help identify new indications for Cytocom's existing pipeline of assets designed to rebalance the body's immune system and restore homeostasis and lead efforts to develop a global network of researchers and scientists to collaborate with Cytocom in new applications for its AIMS™ (Advanced Immunomodulating Multi-Receptor System) drug discovery and development platform. These research and development efforts will focus on using immune modulation to address autoimmune and inflammatory conditions, infectious diseases, age-related pathologies and cancer.